MicroRNAs as potential biomarkers in human solid tumors

Cancer Letters

Volumn 329, Issue 2, 2013, Pages 125-136

  Shen, Jun ^a   Stass, Sanford A ^a   Jiang, Feng ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Cancer; Circulation; Diagnosis; MicroRNA; Prognosis

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 126; MICRORNA 136; MICRORNA 141; MICRORNA 143; MICRORNA 146; MICRORNA 149; MICRORNA 155; MICRORNA 182; MICRORNA 183; MICRORNA 184; MICRORNA 195; MICRORNA 198; MICRORNA 202; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 221; MICRORNA 223; MICRORNA 25; MICRORNA 345; MICRORNA 375; MICRORNA 498; MICRORNA 503; MICRORNA 513; MICRORNA 708; MICRORNA 96; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; COLORECTAL CANCER; EARLY DIAGNOSIS; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RNA ANALYSIS; RNA STABILITY; SERUM; SHORT SURVEY; SOLID TUMOR; STOMACH CANCER;

EID: 84872496432     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.001     Document Type: Review

References (143)

1. Iorio M.V., Croce C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 2012, 4:143-159.
2. Nana-Sinkam P., Croce C.M. MicroRNAs in diagnosis and prognosis in cancer: what does the future hold?. Pharmacogenomics 2010, 11:667-669.
3. Taft R.J., Pang K.C., Mercer T.R., Dinger M., Mattick J.S. Non-coding RNAs: regulators of disease. J. Pathol. 2010, 220:126-139.
4. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 2011, 8:467-477.
5. Kunej T., Godnic I., Ferdin J., Horvat S., Dovc P., Calin G.A. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat. Res. 2011, 717:77-84.
6. Qu H., Xu W., Huang Y., Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pacific J. Cancer Prev. 2011, 12:1117-1125.
7. Duttagupta R., Jiang R., Gollub J., Getts R.C., Jones K.W. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011, 6:e20769.
8. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., Galas D.J., Wang K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56:1733-1741.
9. Molina-Pinelo S., Suarez R., Pastor M.D., Nogal A., Marquez-Martin E., Martin-Juan J., Carnero A., Paz-Ares L. Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Dis. Markers 2012, 32:221-230.
10. Kosaka N., Izumi H., Sekine K., Ochiya T. MicroRNA as a new immune-regulatory agent in breast milk. Silence 2010, 1:7.
11. Xie Y., Todd N.W., Liu Z., Zhan M., Fang H., Peng H., Alattar M., Deepak J., Stass S.A., Jiang F. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010, 67:170-176.
12. Yu L., Todd N.W., Xing L., Xie Y., Zhang H., Liu Z., Fang H., Zhang J., Katz R.L., Jiang F. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 2010, 127:2870-2878.
13. Saito M., Schetter A.J., Mollerup S., Kohno T., Skaug V., Bowman E.D., Mathe E.A., Takenoshita S., Yokota J., Haugen A., Harris C.C. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin. Cancer Res. 2011, 17:1875-1882.
14. Shen J., Todd N.W., Zhang H., Yu L., Lingxiao X., Mei Y., Guarnera M., Liao J., Chou A., Lu C.L., Jiang Z., Fang H., Katz R.L., Jiang F. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 2011, 91:579-587.
15. Shen J., Liu Z., Todd N.W., Zhang H., Liao J., Yu L., Guarnera M.A., Li R., Cai L., Zhan M., Jiang F. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011, 11:374.
16. Shen J., Jiang F. Applications of microRNAs in the diagnosis and prognosis of lung cancer. Expert Opin. Med. Diagn. 2012, 6:197-207.
17. Xing L., Todd N.W., Yu L., Fang H., Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol. 2010, 23:1157-1164.
18. Park N.J., Zhou H., Elashoff D., Henson B.S., Kastratovic D.A., Abemayor E., Wong D.T. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 2009, 15:5473-5477.
19. Hanke M., Hoefig K., Merz H., Feller A.C., Kausch I., Jocham D., Warnecke J.M., Sczakiel G. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 2010, 28:655-661.
20. Chen X., Liang H., Zhang J., Zen K., Zhang C.Y. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012, 22:125-132.
21. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., Xiao T., Schafer J., Lee M.L., Schmittgen T.D., Nana-Sinkam S.P., Jarjoura D., Marsh C.B. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3:e3694.
22. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285:17442-17452.
23. Skog J., Würdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., Curry W.T., Carter B.S., Krichevsky A.M., Breakefield X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10:1470-1476.
24. van Niel G., Porto-Carreiro I., Simoes S., Raposo G. Exosomes: a common pathway for a specialized function. J. Biochem. 2006, 140:13-21.
25. Brase J.C., Wuttig D., Kuner R., Sültmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol. Cancer 2010, 9:306.
26. Valenti R., Huber V., Iero M., Filipazzi P., Parmiani G., Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007, 67:2912-2915.
27. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., Baran J., Zembala M. Tumour-derived microvesicles modulate biological activity of human monocytes. Immunol. Lett. 2007, 113:76-82.
28. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105:10513-10518.
29. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Zen K., Zhang C.Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
30. Kosaka N., Iguchi H., Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101:2087-2092.
31. Zhu W., Qin W., Atasoy U., Sauter E.R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes 2009, 2:89.
32. Fabbri M. MiRNAs as molecular biomarkers of cancer. Expert Rev. Mol. Diagn. 2010, 10:435-444.
33. Szafranska A.E., Davison T.S., Shingara J., Doleshal M., Riggenbach J.A., Morrison C.D., Jewell S., Labourier E. Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. J. Mol. Diagn. 2008, 10:415-423.
34. Simpson R.J., Lim J.W., Moritz R.L., Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev. Proteomics 2009, 6:267-283.
35. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
36. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2:569-579.
37. Michael A., Bajracharya S.D., Yuen P.S., Zhou H., Star R.A., Illei G.G., Alevizos I. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 2010, 16:34-38.
38. Resnick K.E., Alder H., Hagan J.P., Richardson D.L., Croce C.M., Cohn D.E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 2009, 112:55-59.
39. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110:13-21.
40. Rabinowits G., Gercel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10:42-46.
41. Ohshima K., Inoue K., Fujiwara A., Hatakeyama K., Kanto K., Watanabe Y., Muramatsu K., Fukuda Y., Ogura S., Yamaguchi K., Mochizuki T. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One 2010, 5:e13247.
42. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
43. Wang K., Zhang S., Weber J., Baxter D., Galas D.J. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucl. Acids Res. 2010, 38:7248-7259.
44. Zhu H., Fan G.C. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am. J. Cardiovasc. Dis. 2011, 1:138-149.
45. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., Mitchell P.S., Bennett C.F., Pogosova-Agadjanyan E.L., Stirewalt D.L., Tait J.F., Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA 2011, 108:5003-5008.
46. Chim S.S., Shing T.K., Hung E.C., Leung T.Y., Lau T.K., Chiu R.W., Lo Y.M. Detection and characterization of placental microRNAs in maternal plasma. Clin. Chem. 2008, 54:482-490.
47. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., Banham A.H., Pezzella F., Boultwood J., Wainscoat J.S., Hatton C.S., Harris A.L. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141:672-675.
48. Ji X., Takahashi R., Hiura Y., Hirokawa G., Fukushima Y., Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin. Chem. 2009, 55:1944-1949.
49. Caby M.P., Lankar D., Vincendeau-Scherrer C., Raposo G., Bonnerot C. Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 2005, 17:879-887.
50. Chen C.Z. MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 2005, 353:1768-1771.
51. van Niel G., Raposo G., Candalh C., Boussac M., Hershberg R., Cerf-Bensussan N., Heyman M. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001, 121:337-349.
52. Kirschner M.B., Kao S.C., Edelman J.J., Armstrong N.J., Vallely M.P., van Zandwijk N., Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One 2011, 6:e24145.
53. Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., Tait J.F., Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila) 2012, 5:492-497.
54. Fevrier B., Vilette D., Archer F., Loew D., Faigle W., Vidal M., Laude H., Raposo G. Cells release prions in association with exosomes. Proc. Natl. Acad. Sci. USA 2004, 101:9683-9688.
55. Mardis E.R. The impact of next-generation sequencing technology on genetics. Trends Genet. 2008, 24:133-141.
56. Metzker M.L. Sequencing technologies - the next generation. Nat. Rev. Genet. 2010, 11:31-46.
57. Wyman S.K., Parkin R.K., Mitchell P.S., Fritz B.R., O'Briant K., Godwin A.K., Urban N., Drescher C.W., Knudsen B.S., Tewari M. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009, 4:e5311.
58. Schulte J.H., Marschall T., Martin M., Rosenstiel P., Mestdagh P., Schlierf S., Thor T., Vandesompele J., Eggert A., Schreiber S., Rahmann S., Schramm A. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucl. Acids Res. 2010, 38:5919-5928.
59. Peltier H.J., Latham G.J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14:844-852.
60. Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Newell J., Kerin M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2010, 251:499-505.
61. Tanaka M., Oikawa K., Takanashi M., Kudo M., Ohyashiki J., Ohyashiki K., Kuroda M. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009, 4:e5532.
62. Lin S.C., Liu C.J., Lin J.A., Chiang W.F., Hung P.S., Chang K.W. MiR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis. Oral Oncol. 2010, 46:204-208.
63. Tijsen A.J., Creemers E.E., Moerland P.D., de Windt L.J., van der Wal A.C., Kok W.E., Pinto Y.M. MiR423-5p as a circulating biomarker for heart failure. Circ. Res. 2010, 106:1035-1039.
64. Wang J.F., Yu M.L., Yu G., Bian J.J., Deng X.M., Wan X.J., Zhu K.M. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem. Biophys. Res. Commun. 2010, 394:184-188.
65. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
66. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
67. Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier E., Reinert K.L., Brown D., Slack F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
68. Kumar M.S., Erkeland S.J., Pester R.E., Chen C.Y., Ebert M.S., Sharp P.A., Jacks T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. USA 2008, 105:3903-3908.
69. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
70. Blenkiron C., Goldstein L.D., Thorne N.P., Spiteri I., Chin S.F., Dunning M.J., Barbosa-Morais N.L., Teschendorff A.E., Green A.R., Ellis I.O., Tavare S., Caldas C., Miska E.A. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome. Biol. 2007, 8:R214.
71. Roth C., Rack B., Muller V., Janni W., Pantel K., Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010, 12:R90.
72. Wu Q., Lu Z., Li H., Lu J., Guo L., Ge Q. Next-generation sequencing of microRNAs for breast cancer detection. J. Biomed. Biotechnol. 2011, 2011:597145.
73. Hu Z., Dong J., Wang L.E., Ma H., Liu J., Zhao Y., Tang J., Chen X., Dai J., Wei Q., Zhang C., Shen H. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 2012, 33:828-834.
74. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67:6130-6135.
75. Ozen M., Creighton C.J., Ozdemir M., Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27:1788-1793.
76. Schaefer A., Jung M., Mollenkopf H.J., Wagner I., Stephan C., Jentzmik F., Miller K., Lein M., Kristiansen G., Jung K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010, 126:1166-1176.
77. Brase J.C., Johannes M., Schlomm T., Falth M., Haese A., Steuber T., Beissbarth T., Kuner R., Sultmann H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 2011, 128:608-616.
78. Mahn R., Heukamp L.C., Rogenhofer S., von Ruecker A., Muller S.C., Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011, 77:1265.e9-1265.e16.
79. Nagel R., le Sage C., Diosdado B., van der Waal M., Oude Vrielink J.A., Bolijn A., Meijer G.A., Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008, 68:5795-5802.
80. Slaby O., Svoboda M., Fabian P., Smerdova T., Knoflickova D., Bednarikova M., Nenutil R., Vyzula R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 72:397-402.
81. Akao Y., Nakagawa Y., Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol. 2007, 26:311-320.
82. Lanza G., Ferracin M., Gafa R., Veronese A., Spizzo R., Pichiorri F., Liu C.G., Calin G.A., Croce C.M., Negrini M. MRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer 2007, 6:54.
83. Pu X.X., Huang G.L., Guo H.Q., Guo C.C., Li H., Ye S., Ling S., Jiang L., Tian Y., Lin T.Y. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J. Gastroenterol. Hepatol. 2010, 25:1674-1680.
84. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 2010, 127:118-126.
85. Wang L.G., Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012, 36:e61-67.
86. Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., Liu C.G., Bhatt D., Taccioli C., Croce C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901-1908.
87. Szafranska A.E., Davison T.S., John J., Cannon T., Sipos B., Maghnouj A., Labourier E., Hahn S.A. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007, 26:4442-4452.
88. Wang J., Chen J., Chang P., LeBlanc A., Li D., Abbruzzesse J.L., Frazier M.L., Killary A.M., Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila) 2009, 2:807-813.
89. Ho A.S., Huang X., Cao H., Christman-Skieller C., Bennewith K., Le Q.T., Koong A.C. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl. Oncol. 2010, 3:109-113.
90. Li A., Omura N., Hong S.M., Vincent A., Walter K., Griffith M., Borges M., Goggins M. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010, 70:5226-5237.
91. Morimura R., Komatsu S., Ichikawa D., Takeshita H., Tsujiura M., Nagata H., Konishi H., Shiozaki A., Ikoma H., Okamoto K., Ochiai T., Taniguchi H., Otsuji E. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br. J. Cancer 2011, 105:1733-1740.
92. Ueda T., Volinia S., Okumura H., Shimizu M., Taccioli C., Rossi S., Alder H., Liu C.G., Oue N., Yasui W., Yoshida K., Sasaki H., Nomura S., Seto Y., Kaminishi M., Calin G.A., Croce C.M. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11:136-146.
93. Guo J., Miao Y., Xiao B., Huan R., Jiang Z., Meng D., Wang Y. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J. Gastroenterol. Hepatol. 2009, 24:652-657.
94. Zhou H., Guo J.M., Lou Y.R., Zhang X.J., Zhong F.D., Jiang Z., Cheng J., Xiao B.X. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. (Berl) 2010, 88:709-717.
95. Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., Konishi H., Morimura R., Deguchi K., Fujiwara H., Okamoto K., Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. Br. J. Cancer 2010, 102:1174-1179.
96. Liu H., Zhu L., Liu B., Yang L., Meng X., Zhang W., Ma Y., Xiao H. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012, 316:196-203.
97. Murakami Y., Yasuda T., Saigo K., Urashima T., Toyoda H., Okanoue T., Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25:2537-2545.
98. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008, 47:1955-1963.
99. Li L.M., Hu Z.B., Zhou Z.X., Chen X., Liu F.Y., Zhang J.F., Shen H.B., Zhang C.Y., Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010, 70:9798-9807.
100. Qi P., Cheng S.Q., Wang H., Li N., Chen Y.F., Gao C.F. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011, 6:e28486.
101. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65:6029-6033.
102. Kefas B., Godlewski J., Comeau L., Li Y., Abounader R., Hawkinson M., Lee J., Fine H., Chiocca E.A., Lawler S., Purow B. MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68:3566-3572.
103. Ciafre S.A., Galardi S., Mangiola A., Ferracin M., Liu C.G., Sabatino G., Negrini M., Maira G., Croce C.M., Farace M.G. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 2005, 334:1351-1358.
104. Novakova J., Slaby O., Vyzula R., Michalek J. MicroRNA involvement in glioblastoma pathogenesis. Biochem. Biophys. Res. Commun. 2009, 386:1-5.
105. Gillies J.K., Lorimer I.A. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007, 6:2005-2009.
106. Sempere L.F., Freemantle S., Pitha-Rowe I., Moss E., Dmitrovsky E., Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome. Biol. 2004, 5:R13.
107. Silber J., Lim D.A., Petritsch C., Persson A.I., Maunakea A.K., Yu M., Vandenberg S.R., Ginzinger D.G., James C.D., Costello J.F., Bergers G., Weiss W.A., Alvarez-Buylla A., Hodgson J.G. MiR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008, 6:14.
108. Gal H., Pandi G., Kanner A.A., Ram Z., Lithwick-Yanai G., Amariglio N., Rechavi G., Givol D. MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem. Biophys. Res. Commun. 2008, 376:86-90.
109. Weiss G.J., Bemis L.T., Nakajima E., Sugita M., Birks D.K., Robinson W.A., Varella-Garcia M., Bunn P.A., Haney J., Helfrich B.A., Kato H., Hirsch F.R., Franklin W.A. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 2008, 19:1053-1059.
110. Yu S.L., Chen H.Y., Chang G.C., Chen C.Y., Chen H.W., Singh S., Cheng C.L., Yu C.J., Lee Y.C., Chen H.S., Su T.J., Chiang C.C., Li H.N., Hong Q.S., Su H.Y., Chen C.C., Chen W.J., Liu C.C., Chan W.K., Li K.C., Chen J.J., Yang P.C. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13:48-57.
111. Garofalo M., Di Leva G., Romano G., Nuovo G., Suh S.S., Ngankeu A., Taccioli C., Pichiorri F., Alder H., Secchiero P., Gasparini P., Gonelli A., Costinean S., Acunzo M., Condorelli G., Croce C.M. MiR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16:498-509.
112. Hu Z., Chen X., Zhao Y., Tian T., Jin G., Shu Y., Chen Y., Xu L., Zen K., Zhang C., Shen H. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1721-1726.
113. Wang Z.X., Bian H.B., Wang J.R., Cheng Z.X., Wang K.M., De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J. Surg. Oncol. 2011, 104:847-851.
114. Boeri M., Verri C., Conte D., Roz L., Modena P., Facchinetti F., Calabro E., Croce C.M., Pastorino U., Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl. Acad. Sci. USA 2011, 108:3713-3718.
115. Iorio M.V., Casalini P., Tagliabue E., Menard S., Croce C.M. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur. J. Cancer 2008, 44:2753-2759.
116. Zhu S., Wu H., Wu F., Nie D., Sheng S., Mo Y.Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18:350-359.
117. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., Zeng Y.X., Shao J.Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
118. Diaz L.K., Zhou X., Wright E.T., Cristofanilli M., Smith T., Yang Y., Sneige N., Sahin A., Gilcrease M.Z. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin. Cancer Res. 2005, 11:3309-3314.
119. Huang Q., Gumireddy K., Schrier M., le Sage C., Nagel R., Nair S., Egan D.A., Li A., Huang G., Klein-Szanto A.J., Gimotty P.A., Katsaros D., Coukos G., Zhang L., Pure E., Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 2008, 10:202-210.
120. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
121. Hossain A., Kuo M.T., Saunders G.F. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol. Cell Biol. 2006, 26:8191-8201.
122. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., Sauter G., Kallioniemi O.P., Trent J.M., Meltzer P.S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968.
123. Louie M.C., Zou J.X., Rabinovich A., Chen H.W. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol. Cell Biol. 2004, 24:5157-5171.
124. Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am. J. Pathol. 1999, 154:525-536.
125. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., Gerald W.L., Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
126. Spizzo R., Nicoloso M.S., Lupini L., Lu Y., Fogarty J., Rossi S., Zagatti B., Fabbri M., Veronese A., Liu X., Davuluri R., Croce C.M., Mills G., Negrini M., Calin G.A. MiR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 2010, 17:246-254.
127. Heneghan H.M., Miller N., Kelly R., Newell J., Kerin M.J. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010, 15:673-682.
128. Li X., Zhang Y., Ding J., Wu K., Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010, 59:579-585.
129. Gonzales J.C., Fink L.M., Goodman O.B., Symanowski J.T., Vogelzang N.J., Ward D.C. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer 2011, 9:39-45.
130. Bandres E., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer 2006, 5:29.
131. Cheng H., Zhang L., Cogdell D.E., Zheng H., Schetter A.J., Nykter M., Harris C.C., Chen K., Hamilton S.R., Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011, 6:e17745.
132. Li W., Xie L., He X., Li J., Tu K., Wei L., Wu J., Guo Y., Ma X., Zhang P., Pan Z., Hu X., Zhao Y., Xie H., Jiang G., Chen T., Wang J., Zheng S., Cheng J., Wan D., Yang S., Li Y., Gu J. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer 2008, 123:1616-1622.
133. Fornari F., Gramantieri L., Ferracin M., Veronese A., Sabbioni S., Calin G.A., Grazi G.L., Giovannini C., Croce C.M., Bolondi L., Negrini M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008, 27:5651-5661.
134. Jiang J., Gusev Y., Aderca I., Mettler T.A., Nagorney D.M., Brackett D.J., Roberts L.R., Schmittgen T.D. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 2008, 14:419-427.
135. Yamamoto Y., Kosaka N., Tanaka M., Koizumi F., Kanai Y., Mizutani T., Murakami Y., Kuroda M., Miyajima A., Kato T., Ochiya T. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009, 14:529-538.
136. Borel F., Konstantinova P., Jansen P.L. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J. Hepatol. 2012, 56:1371-1383.
137. Gabriely G., Wurdinger T., Kesari S., Esau C.C., Burchard J., Linsley P.S., Krichevsky A.M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell Biol. 2008, 28:5369-5380.
138. Zhang Y., Chao T., Li R., Liu W., Chen Y., Yan X., Gong Y., Yin B., Qiang B., Zhao J., Yuan J., Peng X. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J. Mol. Med. (Berl) 2009, 87:43-51.
139. Conti A., Aguennouz M., La Torre D., Tomasello C., Cardali S., Angileri F.F., Maio F., Cama A., Germano A., Vita G., Tomasello F. MiR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J. Neurooncol. 2009, 93:325-332.
140. Shi L., Cheng Z., Zhang J., Li R., Zhao P., Fu Z., You Y. Hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008, 1236:185-193.
141. Wang J., Wang Q., Liu H., Hu B., Zhou W., Cheng Y. MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer Lett. 2010, 297:137-143.
142. Cummins J.M., He Y., Leary R.J., Pagliarini R., Diaz L.A., Sjoblom T., Barad O., Bentwich Z., Szafranska A.E., Labourier E., Raymond C.K., Roberts B.S., Juhl H., Kinzler K.W., Vogelstein B., Velculescu V.E. The colorectal microRNAome. Proc. Natl. Acad. Sci. USA 2006, 103:3687-3692.
143. Zhang J., Du Y.Y., Lin Y.F., Chen Y.T., Yang L., Wang H.J., Ma D. The cell growth suppressor, mir-126, targets IRS-1. Biochem. Biophys. Res. Commun. 2008, 377:136-140.